From Yahoo Finance: 2025-05-24 10:51:00

GSK plc (GSK) receives FDA approval for Nucala for COPD and CHMP recommendation for Blenrep in multiple myeloma, boosting sales and analyst projections for 4.6% annual revenue growth over three years. Stock rises 4.9% in past month, outpacing market decline, with fair value estimated at £16.72 per share and potential 18.6% upside. Recent product approvals could strengthen competitive position and drive further gains. While GSK shows growth potential, some AI stocks may offer higher returns with limited downside risk. No promotional or marketing content included in summaries.



Read more at Yahoo Finance: GSK plc (GSK) Stock Rises as FDA Approves Nucala for COPD, CHMP Backs Blenrep for Cancer Treatment